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INTRODUCTION
The mortality and morbidity rate of cervical cancer
globally is 275.000 and 529.000, respectively, making
it the third leading cancer globally and the first lead-
ing cancer in developing country.1-4 Smoking has
been a well-known risk factor for cervical cancer.
According to the WHO in 2008, Indonesia is the
third leading country in number of smoker globally,
with 59.8 million smokers (approximately 225 bil-
lion cigarettes per year), and 2.7% of them are
women. It is estimated that each year there are 2,3
million Indonesian women who are active smokers
while another 1.6 million women are non-cigarette
tobacco users. Tobacco contains carcinogenic mate-
rial; burned tobacco produces polycyclic aromatic
hydrocarbon heterocyclic nitrosamines, which gives
negative effects to people who consume it.
The role of smoking habit as prognostic factor
for cervical cancer patients in Dr. Cipto Mangun-
kusumo Hospital has not been established yet. The
Abstract
Objective: The researchers aim to investigate the relationship bet-
ween smoking habit and other factors as prognostic factors of cervical
cancer.
Method: We performed a retrospective and prospective cohort study
with subjects that are stage IIB-IVB cervical cancer patients in Dr.
Cipto Mangunkusumo Hospital followed up from August 2009 to
April 2014. The subjects’medical records were reviewed, and patients
were interviewed about their current condition by telephone. Ques-
tions asked include smoking habit, spouse’s smoking habit, and mor-
tality status. Patients that could not be contacted by phone were ex-
cluded from the study. Statistical analysis was done using Stata 10.
Result: Out of 390 cervical cancer patients stage IIB-IVB in 2009,
there were 270 patients (69.2%) that were included in the inclusion
criteria. Most of the patients are 40-59 years old (82.2%) and are non-
smokers (91.8%). The most frequent clinicopathological characte-
ristic is IIIB (63.3%) and squamous cell carcinoma (71.9%). The 5-
year survival rate is 22.6%. There is no statistical significance between
advanced stage cervical cancer survival with the patients’ or patients’
husbands’ smoking habit.
Conclusion: In our study, smoking habits do not aggravate survival
rate of advanced stage cervical cancer patients but further research
must be done with more sample. Stage, and tumor size both by physi-
cal examination and ultrasound can be used as the prognostic factor.
[Indones J Obstet Gynecol 2015; 3: 170-176]
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Abstrak
Tujuan: Mengetahui pengaruh merokok terhadap faktor prognosis kan-
ker serviks serta faktor-faktor lain yang berhubungan sehingga dapat
membantu memberikan gambaran mengenai prognosis kanker serviks.
Metode: Penelitian ini adalah kohort retrospektif. Sampel penelitian
adalah pasien kanker serviks stadium IIB-IVB di RS Dr. Cipto Ma-
ngunkusumo mulai dari Agustus 2009 sampai April 2014. Kondisi
terakhir pasien di follow up menggunakan telepon. Kondisi yang di-
nilai adalah pasien masih hidup atau tidak, pasien merokok atau ti-
dak, dan suami pasien merokok atau tidak. Pasien yang tidak dapat
dihubungi akan dieksklusi dari penelitian. Analisa data menggunakan
Stata 10.
Hasil: Dari 390 pasien kanker serviks stadium IIB-IVB, hanya 270 pasien
(69,2%) yang memenuhi criteria inklusi dan eksklusi. Sebagian besar pa-
sien berusia 40-59 tahun (82,2%), tidak merokok (91,8%), suami me-
rokok (73,3%). Karakteristik kliniko patologis yang terbanyak adalah sta-
dium IIIB (63,3%), jenis karsinoma skuamosa (71,9%). Kesintasan 5 ta-
hun pasien kanker serviks adalah 22,6%. Hubungan antara kebiasaan
merokok pasien dan suami dibandingkan dengan kesintasan pasien kanker
serviks menunjukkan hasil yang tidak signifikan.
Kesimpulan: Dalam penelitian kami, kebiasaan merokok tidak mem-
perburuk tingkat kelangsungan hidup penderita kanker serviks stadium
lanjut, tetapi penelitian lebih lanjut harus dilakukan dengan jumlah sam-
pel lebih besar. Stadium, dan ukuran tumor baik dengan pemeriksaan
fisik dan USG dapat digunakan sebagai faktor prognostik.
[Maj Obstet Ginekol Indones 2015; 3: 170-176]
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most well known prognostic factor for cervical can-
cer patient is its stage. Other prognostic factors
contributing to cervical cancer patient outcome is
important to be investigated. Therefore, the study
aims to investigate the relationship between smok-
ing and other factors as prognostic factors of cer-
vical cancer.
METHODS
The study uses cohort retrospective method. Sub-
jects are patients from Dr. Cipto Mangunkusumo
Hospital with advanced stage (Stage IIB-IVB) cer-
vical cancer from August 2009 - April 2014. Demo-
graphic and clinicopathological characteristics were
obtained from medical record. Patients were con-
tacted via telephone, from numbers listed on the
medical record, and asked their mortality status,
smoking habit and husband’s smoking habit. Exclu-
sion criteria include patients who could not be con-
tacted by telephone. Patients’ survival rate was cal-
culated by finding the interval (in days) between
date of death and date of diagnosis. Outcome mea-
sure is survival rate, which is determined by months
after diagnosis. The follow up period is 58 months,
therefore survival until the end of the follow up pe-
riod is considered as 5-year survival rate. Statistical
analysis was done using Stata 10.
RESULTS
Among 390 patients with cervical cancer stage IIB-
IVB in RSCM since August 2009, 270 (69.2%) pa-
tients were successfully interviewed by phone. Sixty
five percent of these patients were referred by rural
hospital, 28.1% patients were referred by gynecolo-
gist and rest of them were referred by primary
health care centers. Occupation of the subjects was
mostly (85.2%) housewives. Patients were divided
into ages above 60 years old (10.4%), between 40-59
years old (82.2%) and below 40 years of age (7.4%).
While, the age of cervical cancer onset were found
mostly in the 40-59 age group with 65% belonging
to this group. Most of the patients (41.1%) has an
undergraduate degree, and 64.1% had 3 children or
more. 89.3% of the patients never had a pap smear
examination before.
The physical examination showed that most of
the subjects (80%) had tumors sized 4-8 centi-
meters, and rest (15.2%) had tumors less than 4 cm.
On ultrasonography findings, only 66.7% of the pa-
tients had 4-8 centimeters tumor. Patients were also
classified into The International Federation of Gy-
necology and Obstetrics (FIGO) stages, results
were as follows: IIB: 22.2%, IIIA: 4.8%, IIIB:
63.3%; and IVA: 9.6%. 85% patients didn’t have
any pelvic lymph node enlargement. From histo-
pathology findings, most patients (71.9%) were
found to have squamous cell carcinoma (SCC) his-
tological subtype; with 66.6% of them being mo-
derately differentiated and 16.7% being well differ-
entiated. 81.3% of the subjects’ tumor cells were
not keratinized, and no lymphovascular invasion
was found in 86.7% of patients. Therapy modalities
were mostly radiotherapy (42.2%) and chemo-
radiation with cisplatin-ifosfamide (30%).
The patients were then divided into the light, mo-
derate and heavy smoker based on the Brigmann’s
Index. Only 8.2% (n=8) of patients admitted to be
a smoker while the rest claim to not smoke; 73.3%
of the subjects’ spouses were smokers.
The average survival rate amongst patients was 22
months (SD= 4-58). While those who made it until
the end of the follow up period (5-year survival rate)
of advanced stage cervical cancer patients was
22.6%. The study showed that survival in the first
year was 86.3%, decreasing to half in the second
year to 43.3%, and kept decreasing to 24.4%, 23.3%,
and 22.6% for the third, fourth, and fifth year, re-
spectively.
Bivariate analysis showed no statistically signifi-
cant relationship between the size of the tumor,
lymphadenopathy, cell differentiation, lymphovas-
cular invasion, keratinization stage of cervical can-
cer, and response to therapy with smoking status
of both the patient and the husband.
Figure 1. Advance Stage Cervical Cancer 5-years Survival
      Rate.
Vol 3, No 3
July 2015 Effect of smoking on cervical cancer survival  171
Table 1 shows that there is a significant relation-
ship between cervical cancer survival rate with the
prognostic factors: tumor size, cell differentiation,
lymphovascular invasion, keratinization, stage of
cervical cancer, and response to therapy based on p-
value<0.25. thus, a multivariate analysis was done re-
vealing that stage and tumor size has a statistically sig-
nificant relationship with survival of cervical cancer.
Table 1. Bivariate Analysis of the Relationship between Prognostic Factor and Survival
B p HR
95%CI
Lower limit Upper limit
Age -0.161 0.317 0.852 0.622 1.167
Parity -0.059 0.599 0.942 0.755 1.176
Pap Smear 0.144 0.504 1.155 0.757 1.762
Tumor size 0.247 0.104 1.281 0.950 1.726
Tumor size USG 0.561 <0.001 1.752 1.354 2.267
Cancer stage 1.518 <0.001 4.564 3.527 5.906
Pelvic lymph node -0.148 0.458 0.863 0.584 1.274
Histopathology 0.054 0.486 1.056 0.906 1.229
Cell differentiation 0.152 0.008 1.164 1.041 1.302
Lymphovascular invasion 0.251 0.220 1.285 0.860 1.919
Brigmann Index -0.029 0.874 0.972 0.679 1.389
Brigmann Index Patient Husband 0.072 0.282 1.075 0.942 1.227
Keratinization 0.192 0.236 1.212 0.882 1.666
Therapy response 0.261 0.066 1.299 .982 1.717
Table 2. Multivariate Analysis of the Relationship between Prognostic Factors and Survival
B p HR
95%CI
Lower limit Upper limit
Tumor size < 4 cm 0.122
Tumor size 4-8 cm 0.366 0.043 1.441 1.011 2.054
Tumor size > 8 cm 0.337 0.272 1.400 0.768 2.555
Cell diff Good 0.885
Cell diff Medium -0.075 0.726 0.928 0.612 1.409
Cell diff Bad 0.041 0.900 1.042 0.551 1.970
Cell diff Good + Medium 0.164 0.580 1.178 0.659 2.107
Cell diff Medium + Bad -0.113 0.706 0.894 0.498 1.604
Lymphovascular invasion -0.096 0.675 0.908 0.580 1.423
Keratinization 0.235 0.220 1.265 0.869 1.841
Stad IIB <0.001
Stad IIIA 3.182 <0.001 24.084 7.420 78.174
Stad IIIB 3.704 <0.001 40.607 14.757 111.740
Stad IVA 5.113 <0.001 166.128 55.508 497.202
Therapy response Complete 0.419
Therapy response Partial 0.154 0.307 1.167 0.868 1.568
Therapy response Progressive 0.379 0.313 1.461 0.700 3.051
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The Kaplan-Meier’s curve supports the result of
the multivariate analysis. The curve shows that tu-
mor size and stage of cervical cancer are associated
with 5-year survival. Patients with 4-8 centimeters
sized tumors were 1.441 times less likely to survive
than tumors sized <4 centimeters. A confidence in-
terval of 99.5% shows that there is a statistically
significant association between cervical cancer stage
and 5-year survival rate.
There is no significant difference in the correla-
tion between active and passive smokers status
(based on Briggman index) with 5-year survival rate
analyzed using the Cox regression. This was shown
every year during the follow-up period (first to fifth
year).
DISCUSSION
In Indonesia, most cases of cervical cancer is found
in its advanced stage, most commonly stage III.5
Based on INASGO Cancer Registry Reports, ad-
vanced stage cervical cancer (IIB-IVA) cases in Dr.
Cipto Mangunkusumo Hospital has reached 71.2%
of all cases of cervical cancer in 2013.6 Cervical can-
cer survival rate is mainly influenced by the size of
the tumor and metastatic organ involvement.7 Over-
all, cervical cancer survival rate will worsen as cancer
stage increases, regardless of other prognostic fac-
tors such as type of therapy or comorbidities.8-10
Five-year survival rate in cervical cancer based on
stage is as follows: IA: 93%, IB: 80%, IIA: 63%,
IIB: 65.8%, IIIA: 39.7%, IIIB: 41.5%, IVA: 22.0%,
and IVB: 9.3%.8-10 This is consistent with our study
(p<0.001). The method used in this study was a
retrospective and prospective cohort. Patients were
phoned to obtain smoking status and were followed
up for 58 months using a prospective cohort me-
thod to calculate survival rate.
Aside from being a risk factor for cervical cancer,
smoking also contributes to lower survival rate.11,12
The mechanism of the detrimental effects of smok-
ing on the incidence of cervical cancer still remains
unclear. However, it is believed, cigarettes sup-
presses the immune system against HPV infection
making patients more prone to infection.13,14 In ad-
dition, smoking causes remodeling of cervical epi-
thelium13 and disrupts tissue oxygenation which im-
pacts the usage of radiation therapy.12 Waggoner et
al, stated that the prognosis of cervical cancer pa-
tients who underwent chemoradiation therapy are
poorer in smoking patients compared to non-smok-
ers patients.12 However, in this study, smoking did
not show significant differences on cervical cancer
survival rate. Supporting our study, Fyles et al ar-
gues that there is no significant difference between
smoking and levels of tissue oxygenation in patients
with cervical cancer.15 Our study showed the pro-
portion of cervical cancer patients who smoke is
8.2% compared to 91.8% who do not smoke. The
low amount of patients who smokes could be a con-
tribution to why our study shows that there is no
significant relationship between smoking and cervi-
cal cancer survival rate.
The effect of being a passive smoker on the sur-
vival rate of cervical cancer is still debatable. A re-
search in China by Cheng et al. concluded that
Table 3. Correlation Patient Smoking Status with 5-years Survival of Cervical Cancer
B p HR
95%CI
Lower limit Upper limit
Brigmann Index 0 0.828
Brigmann Index 1 - 200 0.097 0.720 1.102 0.649 1.872
Brigmann Index 200-600 -0.245 0.628 0.783 0.291 2.107
Table 4. Correlation Patient Husband Smoking Status with 5-years Survival of Cervical Cancer
B p HR
95%CI
Lower limit Upper limit
Brigmann Index 0 0.382
BrigmannIndex 1-200 0.254 0.198 1.289 0.876 1.899
BrigmannIndex 200-600 0.300 0.096 1.350 0.948 1.924
BrigmannIndex > 600 0.135 0.577 1.144 0.713 1.836
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smoking women have a 73% increased risk for cer-
vical cancer.16
Furthermore, this is clarified by Louis et al in
their study which described that the risk only occur
to women with active smoking habits.17 Their re-
search concluded that passive smoking factor could
not be the only deciding factor on whether one
could have cervical cancer. 73.3% of subjects in our
research are passive smokers. However, a flaw in
our method was that the passive smoker patients
were not asked the amount of exposure to cigarette
smoke. Currently, the authors could not find any
other researches investigating the correlation bet-
ween passive smoking and cervical cancer survival
rate and further research with a larger sample size
is needed.
Various studies reveal that age is one of the prog-
nostic factors for cervical cancer survival rate, but
the significance of age as the sole determinant re-
mains unknown.17-20 In this study, age shows no
significant association (p=0.317) with the prognosis
of advanced stage cervical cancer. This is consistent
with Kumari et al,21 which showed that the age of
patients has no significant correlation as a prognos-
tic factor of cervical cancer. This could be due to
most of our subjects (82.2%) are between the ages
40-59 years old. According to literature, age only
affects survival rate of cervical cancer in patients
younger than 35 years old and older than 70 years
old.20-23
Another factor investigated in our study is the
association of multiparity with the incidence of cer-
vical cancer. We found significant relationship bet-
ween parity and cervical cancer survival rate (p-value
= 0.599). However, studies have shown that it is
highly correlated.24,25 According to a multicenter
study, by Muñoz et al25 and Liao et al,26 the rela-
tionship between multiparity and cervical cancer
survival rate is statistically significant (n = 1673; p
<0.0001). The reason for discrepancy between our
study and other studies could be contributed to the
uneven distribution of subjects in our study. At our
study, 64.1% of subjects have parity ≥ 3 in a sample
of only 270, while Muñoz et al conducted a multi-
center study with 1673 subjects and equal distribu-
tion (53.1% were multiparity). Another factor could
be the cut-off point of multiparity in our study (>3
births) are low compared to Muñoz et al, which is
>5 births.
Coldman et al reported that women with a his-
tory of dysplasia, even with three consecutive nega-
tive Pap tests, evidently still have an increased risk
of cervical cancer compared with women with no
history of dysplasia found with Pap smear screen-
ing.27 Mählcket alstated that the pap smear is the
key in reducing the number of deaths from cervical
cancer (n=6799; p=0.003).28 In this study it was
found that a history of pap smear does not provide
a significant association with cervical cancer survival
rate (p=0504). This could be due to fewer numbers
of subjects (n=270), compared with studies of
Mählck et al (n=6799).
Studies have shown that tumor size of cervical
cancer affects survival rate. Smaller tumors have a
better prognosis compared to larger ones.29,30 Vari-
ous publications reveal that tumor size cervical can-
cer stage is a prognostic factor.21,30-33 This is in line
with our results, which indicates size of mass cor-
relates significantly to survival rate of cervical cancer
(p-value<0.001).
Lymph node involvement is known to be poor
prognostic factors for recurrence and survival rate
in patients with cervical cancer. Lymph node in-
volvement is also the basis for determining the
schedule of adjuvant therapy in early-stage cervical
cancer who received surgical therapy manage-
ment.34-36
Locally advanced cervical cancer, which includes
adenosquamous lymph node involvement post-ope-
ratively and involvement of pelvic lymph node,
shown to be a poor prognostic factor as it lowers
survival rate as well as increase incidence of recur-
rence.37 In this study, the presence of metastasis in
the pelvic lymph nodes showed no significant rela-
tionship with cervical cancer survival rate. This can
be explained by the differences in the proportion of
cases with pelvic lymph node involvement and with-
out the involvement of pelvic lymph nodes (14.1%
vs 85.9%).
Squamous cell carcinoma is the most common
type of cervical cancer.38-41 Prognostic significance
of histologic types of cervical cancer cells is still de-
bated. Adenocarcinoma has a worse prognostic va-
lue when compared to squamous cell carcinoma in
predicting cervical cancer survival rate.38-41 In this
study, the prevalence of squamous cell carcinoma is
similar to various reports on the proportion of cases
of cervical cancer by histology types.42,43 However,
in this study, although the patients with squamous
cell carcinoma have a lower survival rate, the rela-
tionship between the two is proven insignificant.
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Keratinization is a prognostic factor in determin-
ing the survival rate of squamous cell carcinoma. In
our study, there is no significant association bet-
ween keratinized squamous cell carcinoma with cer-
vical cancer survival rate (p=0.236). This is in con-
trast to the study by Kumar et al,44 which revealed
that keratinized squamous cell carcinoma provides
a lower survival rate compared with non-keratinized
squamous cell carcinoma. This difference could be
explained by the number of subjects (n = 270) in
our study compared to Kumar et al, as well as un-
balanced ratio between subjects with keratinized and
non-keratinized squamous cell carcinoma (18.7% vs
81.3%). Kumar et al,44 reported total number of
subjects was 68543, showed a balanced ratio be-
tween the two groups of subjects (45.3% vs 54.7%).
According to Crissman et al45 and Reagan et al,46
tumor differentiation as a prognostic factor for sur-
vival rate of cervical cancer is still controversial. The
data from our study showed no significant relation-
ship found between cell differentiation to cervical
cancer survival rate. (p=0.008).
CONCLUSION
The survival rate of advanced staged cervical in the
first year to fifth was 86.3%, 43.3%, 24.4%, 23.3%,
22.6% respectively and the average survival rate in
our study was 22 months (SD = 4-58 months).
There is no statistically significant relationship be-
tween patients and patients’ husbands smoking sta-
tus to advanced stage cervical cancer survival rate.
Furthermore, there is no association between the
patient’s severity of smoking to tumor size, stage
of cervical cancer, response to therapy, cell differen-
tiation and keratinization. A bivariate analysis was
done and showed that tumor size, cell differentia-
tion, lymphovascular invasion, response to therapy,
keratinization and stage of the cervical cancer has a
statistically significant effect on survival rate. How-
ever, the multivariate analysis done showed that
only tumor size and stage of cervical cancer had a
statistically significant impact on survival rate.
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